title: Centrofacial malignant granulomas. Clinicopathologic study of 40 cases and review of the literature.
abstract: An important problem in the treatment of centrofacial ulcerations is to establish a precise diagnosis, since similar clinical and microscopic findings can result from many different causes (as in the centrofacial malignant granuloma syndrome [CFMG]). A comprehensive surgical biopsy protocol (known as SNFMI/GMCF), involving microbiology, parasitology, immunology and pathology laboratories, allowed us to evaluate and to treat 40 cases of CFMG, who form the basis of this report. In 13 of them, specific diagnoses were found and curative treatments could be given. In the remaining 27, the optical microscopy pattern met the criteria for CFMG without identifiable origin or the presence of so-called lethal midline granulomas; however, a more precise evaluation with the help of immunofluorescence studies led to the recognition of malignant lymphoma (ulcerative lymphoma of the midface [ULM]). Most of these lymphomas belonged to the T cell lineage; the others were of B lymphoid origin, or, more rarely, of histiocytic origin. Patients with ULM received radiotherapy and chemotherapy with a response rate of 70.3%; however, the toxicity was significant, with frequent occurrence of chemotherapy-induced neutropenia followed by severe infectious facial cellulitis. Six patients were enrolled in a preliminary open trial of treatment with recombinant alpha-2b interferon with little success. Three patients were treated with radiation therapy only, and survived. Thus, CFMG is a syndrome with specific causes and treatments, requiring multiple extensive biopsies to make the correct diagnosis. The recognition of ULM as the cause of the previously called "lethal midline granulomas" leads logically to the use of chemotherapy with growth factors in order to ameliorate its bad prognosis.
authors.affiliation: Service de médecine interne, Hôpital Saint-Antoine, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Grange
authors.forename: J
authors.initials: J
authors.lastname: Cabane
authors.forename: A
authors.initials: A
authors.lastname: Dubois
authors.forename: M
authors.initials: M
authors.lastname: Raphaël
authors.forename: G
authors.initials: G
authors.lastname: Chomette
authors.forename: G
authors.initials: G
authors.lastname: Lamas
authors.forename: P
authors.initials: P
authors.lastname: Godeau
authors.forename: B
authors.initials: B
authors.lastname: Meyer
authors.forename: J C
authors.initials: JC
authors.lastname: Imbert
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000737:chemistry; D001706:Biopsy; D002648:Child; D002985:Clinical Protocols / Q000592:standards*; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006103:Granuloma, Lethal Midline / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006784:Hospitals, Teaching; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010784:Photomicrography; D011379:Prognosis; D011878:Radiotherapy / Q000592:standards; D011994:Recombinant Proteins; D012074:Remission Induction; D012307:Risk Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins